Home / Business and Economy / GSK Partners Relation Therapeutics for AI Drug Discovery
GSK Partners Relation Therapeutics for AI Drug Discovery
30 Jul
Summary
- Relation Therapeutics collaborates with GSK on AI drug discovery.
- The partnership aims to generate cellular datasets for AI model training.
- The collaboration has a potential value of up to $110 million.
Relation Therapeutics, a British biotechnology company, has entered into a significant research collaboration with pharmaceutical giant GSK. This partnership, announced on Wednesday, July 30, 2026, is poised to generate crucial human cellular datasets. These datasets will be instrumental in training advanced artificial intelligence models.
The primary objective of this collaboration is to identify potential new targets for drug development. The research alliance holds a substantial potential value, reaching up to $110 million. This initiative underscores the growing role of AI in accelerating and enhancing the process of discovering novel therapeutics.
